OCUP Ocuphire Pharma Inc

0.00 (0.0%)
Pre Market
Last Updated: 04:56:04
Delayed by 15 minutes

Register Free for Streaming Quotes & Tools

Register for Free to get streaming quotes, interactive charts, trades, portfolio, live options flow and more.


Draw Mode:

Volume 12
Bid Price 3.49
Ask Price 3.74
News -
Day High


52 Week Range


Day Low
Company Name Stock Ticker Symbol Market Type
Ocuphire Pharma Inc OCUP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.00 0.0% 3.48 04:56:04
Open Price Low Price High Price Close Price Prev Close
Trades Volume Avg Volume 52 Week Range
4 12 - 1.9501 - 6.60
Last Trade Time Type Quantity Stock Price Currency
05:26:38 1 $ 3.74 USD

Ocuphire Pharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
73.11M 21.01M - 39.85M 17.89M 0.85 2.13
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Ocuphire Pharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No OCUP Message Board. Create One! See More Posts on OCUP Message Board See More Message Board Posts

Historical OCUP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week3.924.503.42013.80915,826-0.44-11.22%
1 Month4.004.503.42013.87401,173-0.52-13.0%
3 Months3.854.503.42013.94209,881-0.37-9.61%
6 Months3.596.603.42014.64303,047-0.11-3.06%
1 Year2.016.601.95014.00235,3391.4773.13%
3 Years5.9313.8121.78014.54468,540-2.45-41.32%
5 Years5.9313.8121.78014.54468,540-2.45-41.32%

Ocuphire Pharma Description

Ocuphire Pharma Inc is a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders. Ocuphire's pipeline includes two small molecular product candidates targeting front and back of the eye indications. The Nyxol candidate is being developed for dim light or night vision disturbances, reversal of pharmacologically induced mydriasis, and presbyopia. The second product candidate, APX3330, is being developed for diabetic retinopathy and diabetic macular edema.